Provided by Tiger Trade Technology Pte. Ltd.

Assertio Holdings, Inc.

0.7675
-0.0166-2.12%
Post-market: 0.7521-0.0154-2.01%19:06 EST
Volume:271.94K
Turnover:209.47K
Market Cap:73.87M
PE:-2.54
High:0.7887
Open:0.7720
Low:0.7590
Close:0.7841
52wk High:1.04
52wk Low:0.5137
Shares:96.25M
Float Shares:85.17M
Volume Ratio:0.82
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3018
EPS(LYR):-0.2265
ROE:-24.48%
ROA:-4.17%
PB:0.70
PE(LYR):-3.39

Loading ...

Company Profile

Company Name:
Assertio Holdings, Inc.
Exchange:
NASDAQ
Establishment Date:
2020
Employees:
58
Office Location:
100 South Saunders Road,Suite 300,Lake Forest,Illinois,United States
Zip Code:
60045
Fax:
510 744 8001
Introduction:
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Directors

Name
Position
Mark L. Reisenauer
Director and Chief Executive Officer
Brendan P. O'Grady
Director
David M. Stark
Director
Heather L. Mason
Director
Sigurd C. Kirk
Director
Sravan K. Emany
Director
William T. McKee
Director

Shareholders

Name
Position
Mark L. Reisenauer
Director and Chief Executive Officer
Paul Schwichtenberg
President and Chief Operating Officer
Ajay Patel
Executive Vice President and Chief Financial Officer
Mary E. Pietryga
Executive Vice President and Chief Commercial Officer
Sam Schlessinger
Executive Vice President and General Counsel